e.l.f. Beauty Insider Sold Shares Worth $3,735,637, According to a Recent SEC Filing-March 2024-www.financetom.com

e.l.f. Beauty Insider Sold Shares Worth $3,735,637, According to a Recent SEC Filing

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

e.l.f. Beauty Insider Sold Shares Worth $3,735,637, According to a Recent SEC Filing

Jun 10, 2024 12:49 AM

03:23 AM EDT, 06/10/2024 (MT Newswires) -- Mandy J Fields, Senior Vice President and Chief Financial Officer, on June 03, 2024, sold 20,197 shares in e.l.f. Beauty (ELF) for $3,735,637. Following the Form 4 filing with the SEC, Fields has control over a total of 68,147 shares of the company, with 68,147 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1600033/000161071724000305/xslF345X03/form4.xml

Price: 177.49, Change: -0.14, Percent Change: -0.08

Previous page： BeiGene to Rename as BeOne Medicines Next page： GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BeiGene to Rename as BeOne Medicines

Nov 15, 2024

07:08 AM EST, 11/14/2024 (MT Newswires) -- BeiGene ( BGNE ) said Thursday it plans to change its name to BeOne Medicines, subject to shareholder approval. Once the name change is approved, the company's Nasdaq ticker will change to ONC. The name change is part of the company's global oncology growth strategy. Price: 222.99, Change: -4.06, Percent Change: -1.79 ...

GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment

Nov 15, 2024

07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results. The trial met its key secondary endpoint of overall...

Merck signs up to $3.3 bln cancer drug deal with China-based LaNova

Nov 15, 2024

Nov 14 (Reuters) - Merck ( MRK ) has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck ( MRK ) to take over development of LaNova's LM-299, a drug candidate targeting a protein called PD-1, which...

Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers

Nov 15, 2024

(Reuters) - U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides and fungicides as they plan for spring planting next year, which market analysts said could hit the bottom lines of agrichemical companies like Bayer. Signs of these financial impacts are already emerging. Bayer shares fell sharply to a 20-year low on...